{
    "root": "e59207b4-96c8-4ccb-b322-f0c522035c60",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "PEMETREXED",
    "value": "20230925",
    "ingredients": [
        {
            "name": "PEMETREXED DISODIUM HEPTAHYDRATE",
            "code": "9T47E4OM16",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63723"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        }
    ],
    "indications": {
        "text": "pemetrexed injection folate analog metabolic inhibitor indicated : \u2022 combination pembrolizumab platinum chemotherapy , initial treatment patients metastatic non-squamous non-small cell lung cancer ( nsclc ) , egfr alk genomic tumor aberrations . ( 1.1 ) \u2022 combination cisplatin initial treatment patients locally advanced metastatic , non-squamous nsclc . ( 1.1 ) \u2022 single agent maintenance treatment patients locally advanced metastatic , non-squamous nsclc whose disease progressed four cycles platinum-based first-line chemotherapy . ( 1.1 ) \u2022 single agent treatment patients recurrent , metastatic non-squamous , nsclc prior chemotherapy . ( 1.1 ) limitations : pemetrexed injection indicated treatment patients squamous cell , nsclc . ( 1.1 ) \u2022 initial treatment , combination cisplatin , patients malignant pleural mesothelioma whose disease unresectable otherwise candidates curative surgery . ( 1.2 )",
        "doid_entities": [
            {
                "text": "non-small cell lung cancer (DOID:3908)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3908"
            },
            {
                "text": "lung cancer (DOID:1324)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1324"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "malignant pleural mesothelioma (DOID:7474)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7474"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 recommended dose pemetrexed injection administered pembrolizumab platinum chemotherapy patients creatinine clearance ( calculated cockcroft-gault equation ) 45 ml/min greater 500 mg/m 2 intravenous infusion 10 minutes , administered pembrolizumab prior platinum chemotherapy , day 1 21-day cycle . ( 2.1 ) \u2022 recommended dose pemetrexed injection , administered single agent cisplatin , patients creatinine clearance 45 ml/minute greater 500 mg/m 2 intravenous infusion 10 minutes day 1 21-day cycle . ( 2.1 , 2.2 ) \u2022 initiate folic acid 400 mcg 1000 mcg orally , daily , beginning 7 days prior first dose pemetrexed injection continue 21 days last dose pemetrexed injection . ( 2.4 ) \u2022 administer vitamin b 12 , 1 mg intramuscularly , 1 week prior first dose pemetrexed injection every 3 cycles . ( 2.4 ) \u2022 administer dexamethasone 4 mg orally , twice daily day , day , day pemetrexed injection . ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "supplied pemetrexed injection white-to-light yellow green-yellow lyophilized powder supplied single-dose vials reconstitution intravenous infusion . ndc 0338-0720-01 : carton containing one ( 1 ) single-dose vial 100 mg pemetrexed . ndc 0338-0722-01 : carton containing one ( 1 ) single-dose vial 500 mg pemetrexed . storage handling store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15-30\u00b0c ( 59-86\u00b0f ) [ usp controlled room temperature ] . pemetrexed injection hazardous . follow applicable special handling disposal procedures.1",
    "adverseReactions": "pemetrexed injection contraindicated patients history severe hypersensitivity reaction pemetrexed [ ( 6.1 ) ] .",
    "indications_original": "Pemetrexed for Injection is a folate analog metabolic inhibitor indicated: \u2022 in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) \u2022 in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) \u2022 as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) \u2022 as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use: Pemetrexed for Injection is not indicated for the treatment of patients with squamous cell, NSCLC. ( 1.1 ) \u2022 initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 )",
    "contraindications_original": "\u2022 The recommended dose of Pemetrexed for Injection administered with pembrolizumab and platinum chemotherapy in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m 2 as an intravenous infusion over 10 minutes, administered after pembrolizumab and prior to platinum chemotherapy, on Day 1 of each 21-day cycle. ( 2.1 ) \u2022 The recommended dose of Pemetrexed for Injection, administered as a single agent or with cisplatin, in patients with creatinine clearance of 45 mL/minute or greater is 500 mg/m 2 as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. ( 2.1 , 2.2 ) \u2022 Initiate folic acid 400 mcg to 1000 mcg orally, once daily, beginning 7 days prior to the first dose of Pemetrexed for Injection and continue until 21 days after the last dose of Pemetrexed for Injection. ( 2.4 ) \u2022 Administer vitamin B 12 , 1 mg intramuscularly, 1 week prior to the first dose of Pemetrexed for Injection and every 3 cycles. ( 2.4 ) \u2022 Administer dexamethasone 4 mg orally, twice daily the day before, the day of, and the day after Pemetrexed for Injection administration. ( 2.4 )",
    "warningsAndPrecautions_original": "How Supplied\n                     Pemetrexed for Injection is a white-to-light yellow or green-yellow lyophilized powder supplied in single-dose vials for reconstitution for intravenous infusion. \n                  NDC 0338-0720-01: Carton containing one (1) single-dose vial of 100 mg pemetrexed. \n                  NDC 0338-0722-01: Carton containing one (1) single-dose vial of 500 mg pemetrexed. \n                  \n                     Storage and Handling\n                     \n                        \n                     Store at 25\u00b0C (77\u00b0F); excursions permitted to 15-30\u00b0C (59-86\u00b0F) [see USP Controlled Room Temperature]. \n                        \n                     Pemetrexed for Injection is a hazardous drug. Follow applicable special handling and disposal procedures.1",
    "adverseReactions_original": "Pemetrexed for Injection is contraindicated in patients with a history of severe hypersensitivity reaction to pemetrexed [see Adverse Reactions (6.1)].",
    "drug": [
        {
            "name": "PEMETREXED",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63616"
        }
    ]
}